Overview
- A NeuroMarkers study from Ohio University published in late June used a porphyrinic carbon‑fiber nanosensor to record real‑time nitric oxide (NO) from patient‑derived induced pluripotent stem cells (iPSCs).
- The sensor produced distinct NO baselines in undifferentiated iPSCs: about 6 nM from an autism (ASD) line, 11 nM from an intellectual disability (ID) line, and 65 nM from an unrelated healthy control.
- Both patient cell lines carried the same rare E198K mutation in the B56δ subunit of PP2A, showing that the cells’ chemical activity diverged despite identical genetic change.
- The team highlights potential for an objective, neonatal differential test because iPSCs reflect early brain‑relevant chemistry and measurements did not require differentiating cells into neurons.
- The result is preliminary: sample size was small, the method needs replication, assay standardization, and clinical validation before any real‑world neonatal use or treatment guidance.